Merck Strikes $773M Deal For Privately Held Tilos Therapeutics

Keeping in line with the biotech M&A frenzy seen for much of the year, Merck & Co., Inc. MRK announced a deal Monday to buy Tilos Therapeutics.

Only recently, the pharma giant agreed to buy Peloton Therapeutics in a deal valued at up to $2.2 billion.

What Happened

Merck struck an agreement to buy privately held Tilos, which develops therapies targeting the latent transforming growth factor — or TGT-beta — complex for treating cancer, fibrosis and autoimmune diseases, for up to $773 million, including an upfront payment as well as contingent milestone payments.

"Tilos has developed a compelling portfolio of candidates that employ a novel approach to modulating the potent signaling molecule TGF-beta by binding to latency-associated peptide, with potential applications across a range of disease indications," Dean Li, senior vice president for discovery and translational medicine at Merck Research Laboratories, said in a statement. 

Why It's Important

TGF-beta inhibitors are antibodies that target a protein called latency-associated peptide, and could come in handy to break the in-built or acquired resistance to checkpoint inhibitors such as Merck's Keytruda. They are therefore termed immunotherapy boosters.

A TGF-beta inhibitor when paired with Keytruda can help a patient's immune system track a tumor it might have missed previously.

Merck shares were trading up slightly at $82.49 at the time of publication Monday. 

Related Links:

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

PolarityTE Shares Rally On Positive Readout From Skin Graft Study In Diabetic Foot Ulcers

Posted In: BiotechM&ANewsTrading IdeasTilos Therapeutics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...